Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

MaxCyte (MXCT) Share News

IN BRIEF: MaxCyte inks deal with Legend Biotech for tech supply

22nd May 2024 21:51

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Inks strategic platform license agreement with Legend Biotech Corp, a firm focused in cell therapy. Under the terms of the agreement, Legend Biotech will get a non-exclusive worldwide license to use MaxCyte's Flow Electroporation technology and ExPERT platform in connection with the research, clinical development and commercialisation of cell-based therapeutical products. Accordingly, MaxCyte will be allowed to receive annual licensing fees and milestones from Legend during clinical development. Read More

MaxCyte shares rise amid double-digit revenue increase

8th May 2024 09:46

(Alliance News) - MaxCyte Inc on Wednesday reported a jump in its first quarter revenue, which it said was driven by its core business sales. Read More

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

3rd May 2024 09:14

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday: Read More

UK earnings, trading statements calendar - next 7 days

30th Apr 2024 14:38

TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout

2nd Apr 2024 15:19

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25%

13th Mar 2024 11:54

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Net loss widens to USD37.9 million in 2023 from USD23.6 million in 2022, as revenue declines by 6.7% to USD41.3 million from 44.3 million. Core business revenue falls by 25% to USD29.8 million from USD39.6 million, but strategic platform license programme-related revenue more than doubles to USD11.5 million from USD4.6 million. In the fourth quarter alone, revenue is USD15.7 million, up 26% from USD12.4 million a year before, as core business revenue falls by 32% but SPL revenue more than quadruples. Read More

EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit

5th Mar 2024 20:43

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

UK earnings, trading statements calendar - next 7 days

5th Mar 2024 16:06

IN BRIEF: MaxCyte signs licencing deal with cell therapy company Wugen

30th Jan 2024 13:58

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Signs strategic platform licence with Wugen Inc, a US-based clinical-stage biotech company developing off-the-shelf cell therapies for the treatment of hematological and solid cancer tumour malignancies. Wugen's lead program is evaluating WU-CART-007, a cell therapy for the treatment of relapsed or refractory T-cell acute lymphoblastic leukaemia. Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte's unique Flow electroporation technology and its trademarked ExPERT research platform. In exchange, MaxCyte will receive annual licence fees and programme-related revenue, although precise transaction details were not provided. Read More

IN BRIEF: MaxCyte chief scientific officer leaves firm

29th Jan 2024 17:56

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Announces departure of Cenk Sumen as chief scientific officer, but he will remain on advisory board. Read More

TRADING UPDATES: Esken's Southend Airport faces further allegations

23rd Jan 2024 18:39

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

MaxCyte's strategic platform licences redeem otherwise modest results

9th Jan 2024 12:18

(Alliance News) - MaxCyte Inc on Tuesday said that promising returns from its strategic platform licence program had bolstered its quarterly revenue expectations. Read More

MaxCyte teams with Singapore-based Lion to support TCR-T cell work

3rd Jan 2024 14:04

(Alliance News) - MaxCyte Inc on Wednesday said it had signed a strategic platform licence with Lion TCR to promote the latter's T cell receptor-T cell pipeline. Read More

TRADING UPDATES: Technology Minerals identifies lithium at Knockeen

12th Dec 2023 15:56

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

EARNINGS AND TRADING: Chapel Down hopes to make splash on AIM

9th Nov 2023 14:14

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

UK earnings, trading statements calendar - next 7 days

1st Nov 2023 15:44

AIM WINNERS & LOSERS: SDX Energy receives gas prepayment from Citic

5th Oct 2023 10:16

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More

MaxCyte shares fall as warns of sharp revenue drop, citing volatility

5th Oct 2023 10:08

(Alliance News) - MaxCyte Inc on Thursday said it expects revenue in the third quarter and for all of 2023 to fall from a year before, citing volatility in customer activity in the life science tools sector. Read More

MaxCyte shares fall as revenue plummets in first half, loss widens

10th Aug 2023 10:22

(Alliance News) - MaxCyte Inc on Thursday reported an increased loss in the first half of 2023, as revenue fell while costs increased. Read More

UK earnings, trading statements calendar - next 7 days

2nd Aug 2023 15:46

FTSE 100 Latest

Value8,774.65

Change-17.15